We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mallinckrodt Enrolls First Patient in Liver Disease Study
Read MoreHide Full Article
Mallinckrodt plc announced that it has enrolled the first patient in a phase IIa study on its investigational oral drug MNK-6106 (L-ornithine phenylacetate) for treating hepatic (liver) cirrhosis and hepatic encephalopathy (HE).
The mid-stage study is evaluating the pharmacokinetics, pharmacodynamics and safety of oral MNK-6106 compared with Xifaxan (rifaximin) for addressing the given patient population. The endpoints of the study are to see the absolute and percentage change in plasma ammonia from baseline within a period of baseline to day five.
Mallinckrodt expects to complete the study by the first quarter of 2020.
Notably, in December 2017, Mallinckrodt acquired the privately held biopharmaceutical company Ocera Therapeutics, Inc. for approximately $42.4 million. Following this, the company bought Ocera’s primary development product MNK6106 and the investigational intravenous drug MNK-6105.
The oral formulation — MNK-6106 — is an ammonia scavenger, which is being developed for the treatment of HE, a complicated acute or chronic liver disease. If approved, the candidate may have the potential to reduce the risk of recurrent HE episodes and rehospitalization for such patients.
Mallinckrodt also plans to start recruiting subjects by this year-end in a phase III clinical study on MNK-6105 for treating patients with acute HE.
Shares of Mallinckrodt have plunged 69.5% so far this year, underperforming the industry’s decrease of 7.5%.
We would like to remind investors that Mallinckrodt is striving hard to diversify its portfolio. In May, the company completed enrolling patients in a late-stage study on its pipeline candidate terlipressin, which is being developed for the treatment of Hepatorenal Syndrome type 1 (HRS 1).
Top-line data from the study is expected in the next three months. Mallinckrodt plans to file a new drug application (NDA) in early 2020, if results from the analysis are found to be supportive.
Another late-stage program on its investigational regenerative skin tissue, StrataGraft, is under phase III development for the treatment of deep partial thickness burns and in phase II stage for full thickness burns.
If approved, these should drive the company’s long-term growth.
ProQR Therapeutics’ loss per share estimates have been narrowed 3% for 2019 and 4.9% for 2020 over the past 60 days.
Celldex’s loss per share estimates have been narrowed 17.1% for 2019 and 8.7% for 2020 over the past 60 days.
Compugen’s loss per share estimates have been narrowed 16.7% for 2019 and 16.3% for 2020 over the past 60 days. The stock has soared 66.3% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Mallinckrodt Enrolls First Patient in Liver Disease Study
Mallinckrodt plc announced that it has enrolled the first patient in a phase IIa study on its investigational oral drug MNK-6106 (L-ornithine phenylacetate) for treating hepatic (liver) cirrhosis and hepatic encephalopathy (HE).
The mid-stage study is evaluating the pharmacokinetics, pharmacodynamics and safety of oral MNK-6106 compared with Xifaxan (rifaximin) for addressing the given patient population. The endpoints of the study are to see the absolute and percentage change in plasma ammonia from baseline within a period of baseline to day five.
Mallinckrodt expects to complete the study by the first quarter of 2020.
Notably, in December 2017, Mallinckrodt acquired the privately held biopharmaceutical company Ocera Therapeutics, Inc. for approximately $42.4 million. Following this, the company bought Ocera’s primary development product MNK6106 and the investigational intravenous drug MNK-6105.
The oral formulation — MNK-6106 — is an ammonia scavenger, which is being developed for the treatment of HE, a complicated acute or chronic liver disease. If approved, the candidate may have the potential to reduce the risk of recurrent HE episodes and rehospitalization for such patients.
Mallinckrodt also plans to start recruiting subjects by this year-end in a phase III clinical study on MNK-6105 for treating patients with acute HE.
Shares of Mallinckrodt have plunged 69.5% so far this year, underperforming the industry’s decrease of 7.5%.
We would like to remind investors that Mallinckrodt is striving hard to diversify its portfolio. In May, the company completed enrolling patients in a late-stage study on its pipeline candidate terlipressin, which is being developed for the treatment of Hepatorenal Syndrome type 1 (HRS 1).
Top-line data from the study is expected in the next three months. Mallinckrodt plans to file a new drug application (NDA) in early 2020, if results from the analysis are found to be supportive.
Another late-stage program on its investigational regenerative skin tissue, StrataGraft, is under phase III development for the treatment of deep partial thickness burns and in phase II stage for full thickness burns.
If approved, these should drive the company’s long-term growth.
Zacks Rank & Stocks to Consider
Mallinckrodt currently carries a Zacks Rank #3 (Hold). Better-ranked stocks from the healthcare sector include ProQR Therapeutics N.V. (PRQR - Free Report) , Celldex Therapeutics, Inc. (CLDX - Free Report) and Compugen Ltd. (CGEN - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
ProQR Therapeutics’ loss per share estimates have been narrowed 3% for 2019 and 4.9% for 2020 over the past 60 days.
Celldex’s loss per share estimates have been narrowed 17.1% for 2019 and 8.7% for 2020 over the past 60 days.
Compugen’s loss per share estimates have been narrowed 16.7% for 2019 and 16.3% for 2020 over the past 60 days. The stock has soared 66.3% so far this year.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>